Physician

Trinidad Atayoc Lim, M.D.

According to 2025 Medicare claims, Trinidad Lim, M.D. (NPI: 1598716979) practices nephrology in the Yuma, AZ market, with the plurality of this provider's patient population coming from Yuma, AZ. This provider's primary affiliated billing organization is YUMA NEPHROLOGY PC (NPI: 1235185729; TIN: 860820509) and primary practice location at 85365-9998.

Lim's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 761 traditional Medicare patients, billed 15,471 HCPCS/CPT codes, and received $291,684 in Medicare payments. The top billing code was 36415 (Insertion of needle into vein for collection of blood sample). Part D data shows 3,137 prescription claims across 562 beneficiaries totaling $690,603 in drug costs, led by Lokelma (Sodium Zirconium Cyclosilicate). DME data shows 245 claims. Open Payments data shows 18 records totaling $702. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $442,369 to $291,684. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	748	41,722	$442,369
2016	906	50,294	$437,501
2017	887	45,753	$409,745
2018	853	46,741	$473,816
2019	1,109	49,717	$543,708
2020	870	32,388	$459,482
2021	695	15,342	$319,277
2022	623	15,162	$305,514
2023	708	10,731	$275,392
2024	761	15,471	$291,684

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	414	4,594	$760,096
2016	481	5,123	$839,812
2017	467	4,739	$808,023
2018	482	4,192	$501,757
2019	506	3,666	$420,738
2020	442	3,272	$548,518
2021	411	2,840	$446,595
2022	450	2,862	$511,603
2023	461	2,522	$587,618
2024	562	3,137	$690,603

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	34	328	$14,982
2016	24	349	$16,660
2017	N/R	307	$13,355
2018	N/R	345	$16,623
2019	67	565	$17,021
2020	34	514	$15,904
2021	N/R	291	$7,095
2022	N/R	229	$4,232
2023	11	270	$5,119
2024	N/R	245	$3,271

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
36415	Insertion of needle into vein for collection of blood sample	336	827	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	290	587	$8
82570	Creatinine level to test for kidney function or muscle injury	289	512	$5
84156	Total protein level, urine	287	512	$4
81001	Manual urinalysis test with examination using microscope, automated	292	517	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lokelma	Sodium Zirconium Cyclosilicate	167	6,834	$153,463
Jardiance	Empagliflozin	148	7,050	$123,593
Velphoro	Sucroferric Oxyhydroxide	37	1,239	$106,050
Farxiga	Dapagliflozin Propanediol	73	3,348	$59,334
Kerendia	Finerenone	54	2,280	$42,925

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	80	$940
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	49	$855
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	45	$818
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	49	$643
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	22	$15

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	18	$702	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Trinidad Atayoc Lim, M.D.?

Tedicare shows public-source Medicare data for Trinidad Atayoc Lim, M.D. (NPI 1598716979), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Trinidad Atayoc Lim, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Trinidad Atayoc Lim, M.D.?

Trinidad Atayoc Lim, M.D. is linked to YUMA NEPHROLOGY PC (billing NPI 1235185729) in the available physician profile data.

Does Trinidad Atayoc Lim, M.D. have Open Payments data?

Trinidad Atayoc Lim, M.D. has 18 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.